Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
August 28, 2012 · Comments Off
Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
University of Colorado Cancer Center researcher recognized in quest to eradicate lung cancer
June 8, 2012 · Comments Off
Ross Camidge, MD, PhD, recipient of Addario Lectureship Award An investigator for the University of...
Low testosterone with new lung cancer drug — if recognized, easy to fix
April 5, 2012 · Comments Off
Men experience a marked drop in their testosterone levels when taking a targeted therapy to...
Cancer survivor to test lungs at Livestrong Austin Half Marathon
February 15, 2012 · Comments Off
For lung cancer survivor Matt Ellefson, the Livestrong Austin Half Marathon is about more than...
People with specific kind of lung cancer respond to new targeted treatment
October 28, 2010 · Comments Off
A study in the New England Journal of Medicine shows more than half of patients...
UCCC offers ALK positive lung cancer clinical trial
February 19, 2010 · Comments Off
Learn more about the trial Aurora, Colo. (Feb. 19 2010) — The University of Colorado...
Bitter melon juice prevents pancreatic cancer in mouse models
February 19, 2010
Promising Breast and Ovarian Cancer Treatment Vaccine Comes to UCH
February 19, 2010
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer grants cancer research colorado Cancer Survivorship clinical trial colon cancer colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu enzalutamide fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
Remember! "Cancer: The Emperor of All Maladies" starts tonight at 8. You will not want to miss this! ow.ly/KZ956